Lindsay Julian N, Barras Michael
Royal North Shore Hospital, Sydney, Australia
Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
J Oncol Pharm Pract. 2015 Aug;21(4):293-5. doi: 10.1177/1078155214527859. Epub 2014 Mar 24.
With the emergence of new oral therapies for metastatic melanoma to the market, as well as ongoing pre-marketing trials and special access schemes, it is important to keep up to date with the side effect profiles of these medications. A common side effect associated with the BRAF inhibitor dabrafenib is severe fever symptoms such as pyrexia and rigors/chills; however, treatment options are limited. We report a patient who was debilitated by severe pyrexia and rigors caused by dabrafenib used in combination with trametinib to treat metastatic melanoma, who was treated with low-dose steroids. To our knowledge, the use of prednisolone for the treatment and prevention of further dabrafenib-associated pyrexia is not published; however, it is a low risk and low cost option that was very effective in this case.
随着转移性黑色素瘤新型口服疗法进入市场，以及正在进行的上市前试验和特殊获取计划，及时了解这些药物的副作用情况很重要。与BRAF抑制剂达拉非尼相关的一种常见副作用是严重发热症状，如发热和寒战；然而，治疗选择有限。我们报告了一名患者，其因使用达拉非尼联合曲美替尼治疗转移性黑色素瘤而出现严重发热和寒战，身体虚弱，接受了低剂量类固醇治疗。据我们所知，使用泼尼松龙治疗和预防与达拉非尼相关的进一步发热尚未见报道；然而，这是一种低风险、低成本的选择，在该病例中非常有效。
